Skip to main content

Beatriz Minguez Rosique

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Beatriz Minguez Rosique

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Research lines

Càncer hepàtic

Biòpsia liquida en carcinoma hepatocel·lular

Biomarcadors de carcinoma hepatocel·lular

Efectes de la suplementació del Zinc en models preclínics de carcinoma hepatocel·lular

Assaigs clínics per carcinoma hepatocel·lular

IP: Beatriz Minguez Rosique

Projects

ARTEMIs: AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients

IP: José Raul Herance Camacho
Collaborators: Beatriz Minguez Rosique, Clara Ramírez Serra, Cristina Gamez Cenzano, Juan Manuel Pericàs Pulido, Nuria Roson Gradaille, Andreea Ciudin Mihai, Alberto Roque Pérez, Queralt Martin Saladich, Maria Nazarena Pizzi, Ramón Vilallonga Puy
Funding agency: EUROPEAN COMMISSION
Funding: 724000
Reference: ARTEMIS_HE-HLTH2023
Duration: 01/01/2024 - 31/12/2027

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria Buti Ferret, Montserrat Gomez Perez, Judit Romero Vico, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Aislamiento y caracterización molecular de Células Tumorales Circulantes (CTCs): potenciales biomarcadores en Carcinoma Hepatocelular

IP: Beatriz Minguez Rosique
Collaborators: Itxarone Izaskun Bilbao Aguirre, Elena Vargas Accarino, Maria Teresa Salcedo Allende, Monica Higuera Urbano
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI21/00714
Duration: 01/01/2022 - 31/12/2025

Utilidad de la biopsia líquida en el diagnóstico molecular, seguimiento y manejo terapéutico del carcinoma hepatocelular.

IP: Beatriz Minguez Rosique
Collaborators: Itxarone Izaskun Bilbao Aguirre, Maria Teresa Salcedo Allende, Monica Higuera Urbano
Funding agency: Instituto de Salud Carlos III
Funding: 129470
Reference: PI18/00961
Duration: 01/01/2019 - 31/12/2022

Related news

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Antonio Segura García

Antonio Segura García

Administration and Management
Read more
Pablo Castillo Sánchez

Pablo Castillo Sánchez

Research technician
Neurodegenerative Diseases
Read more
Marcella Salzano

Marcella Salzano

Research technician
Liver Diseases
Read more
Maria Florencia Pilia

Maria Florencia Pilia

Predoctoral researcher
Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.